According to one scholarly analysis of the Rezulin disaster, “company and government documents . . . showed that officials from Warner-Lambert had collaborated closely with certain senior officials in the US Food and Drug Administration (FDA) during the approval process and later, when the company was being pressured to take the drug off the market.”
